In contrast to Merck (NYSE: MRK ) , Sanofi (NYSE: SNY )
is stepping up in a big way to gain exposure to the RNA interference
(RNAi) therapeutic class. Sanofi announced Monday morning that it would
acquire a 12% stake in Alnylam (NASDAQ: ALNY )
as well as forge a far-reaching partnership for multiple pipeline
projects under way at Alnylam. With this deal, Sanofi gets a valuable
"seal of approval" from Big Pharma and will also significantly expand
its commercialization options for its pipeline. For Sanofi, the company
gains access to a therapeutic/treatment approach to rare diseases where
IP is precious and where sentiment has shifted from enthusiasm to
despair and back again to rampant enthusiasm.
Please continue here:
Sanofi Takes A Deep Dive Into RNA With Alnylam Deal
No comments:
Post a Comment